drugset / Trial / NCT01345357
Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of the study is to determine the maximum tolerated dose (MTD) of CEP-9722 in combination with gemcitabine and cisplatin in patients with advanced solid tumors or mantle cell lymphoma.
Timeline
- Start
- 2011-05
- Primary completion
- 2012-12
- Completion
- 2013-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CEP-9722 | Small molecule | 150 mg | Oral |
| Subject | CEP-9722 | Small molecule | 200 mg | Oral |
| Subject | CEP-9722 | Small molecule | 300 mg | Oral |
| Subject | CEP-9722 | Small molecule | 400 mg | Oral |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Background | Gemcitabine | Small molecule | 1250 mg/m2 | Intravenous |